Torudokimab (ZB-880)

About Zura Bio

Zura Bio's mission is to dramatically improve the lives of patients with severe autoimmune and inflammatory conditions by developing novel medicines based on dual-pathway antagonism. Since its 2022 founding, the company has rapidly built a promising clinical pipeline through the strategic in-licensing of three assets from Eli Lilly and Pfizer, culminating in a public listing via SPAC merger in 2023. With a seasoned leadership team and over $400 million raised to date, Zura is advancing its lead candidate, tibulizumab, through Phase 2 proof-of-concept studies, positioning itself as a capital-efficient disruptor in the autoimmune therapeutics space.

Therapeutic Areas